Aspen Pharmacare Holdings Ltd banner
A

Aspen Pharmacare Holdings Ltd
OTC:APNHY

Watchlist Manager
Aspen Pharmacare Holdings Ltd
OTC:APNHY
Watchlist
Price: 8.4 USD Market Closed
Market Cap: $3.7B

P/FCFE

-413.3
Current
1 745%
Cheaper
vs 3-y average of 25.1

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-413.3
=
Market Cap
$63.4B
/
Free Cash Flow to Equity
-149.3m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-413.3
=
Market Cap
$63.4B
/
Free Cash Flow to Equity
-149.3m

Valuation Scenarios

Aspen Pharmacare Holdings Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (25.1), the stock would be worth $-0.51 (106% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-106%
Maximum Upside
No Upside Scenarios
Average Downside
105%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple -413.3 $8.4
0%
3-Year Average 25.1 $-0.51
-106%
5-Year Average 20 $-0.41
-105%
Country Average 21.1 $-0.43
-105%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
ZA
Aspen Pharmacare Holdings Ltd
OTC:APNHY
61.7B USD -413.3 -30.9
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
ZA
A
Aspen Pharmacare Holdings Ltd
OTC:APNHY
Average P/E: 523.3
Negative Multiple: -30.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

Lower than 100% of companies in South Africa
Percentile
0th
Based on 10 companies
0th percentile
-0.2
Low
11.2 — 21.1
Typical Range
21.1 — 22.7
High
22.7 —
Distribution Statistics
South Africa
Min 11.2
30th Percentile 21.1
Median 21.1
70th Percentile 22.7
Max 26.3

Aspen Pharmacare Holdings Ltd
Glance View

Market Cap
3.7B USD
Industry
Pharmaceuticals

In the vibrant world of global pharmaceuticals, Aspen Pharmacare Holdings Ltd. stands out as a beacon of South African innovation and business acumen. Founded in Durban in 1997, Aspen has grown from modest beginnings into a multinational powerhouse. The company’s core strength lies in manufacturing and producing a diversified portfolio of pharmaceutical products, including generic medications, branded pharmaceuticals, and over-the-counter consumer health products. It further engages in anesthetics, nutritional products, and critical care drugs, offering solutions to myriad health challenges across more than 50 countries. This diversification not only ensures a broad market appeal but effectively hedges against the risks inherent in the pharmaceutical sector, such as patent expirations and regulatory hurdles. Aspen’s financial blueprint is designed around strategic partnerships and manufacturing competencies that serve both developed and emerging markets. It generates revenue primarily through its extensive distribution network and its ability to produce cost-effective generics that address high-demand therapeutic areas, such as cardiovascular, diabetes, and cancer treatments. The company’s growth is fuelled by both organic expansion and astute acquisitions, such as the incorporation of select portfolios from global giants like GlaxoSmithKline. Aspen meticulously balances manufacturing efficiency with stringent regulatory compliance, operated through state-of-the-art facilities accredited by international regulatory bodies. By maintaining this commitment to quality and cost-efficiency, Aspen differentiates itself from competitors and consolidates its position as a significant player in the global pharmaceutical landscape.

APNHY Intrinsic Value
Not Available
A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett